Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad has maintained an Overweight rating on Amneal Pharmaceuticals (NASDAQ:AMRX) and increased the price target from $6 to $8.
January 29, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays analyst Balaji Prasad maintains an Overweight rating on Amneal Pharmaceuticals and raises the price target from $6 to $8, indicating a positive outlook on the stock.
The increase in price target by Barclays reflects a bullish stance on Amneal Pharmaceuticals, suggesting that the analyst sees potential for the stock to rise. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100